| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Environmental Risk Research Division, National Institute for Environmental Studies, Ibaraki 305-0053, Japan [M. K.]; Departments of Epidemiology [S. A.] and Clinical Studies [K. N.], Radiation Effects Research Foundation, Hiroshima 732-0815, Japan; Department of Public Health, Faculty of Medicine, Kagoshima University, Kagoshima 890-0075, Japan [S. A.]; Pacific Northwest National Laboratory, Richland, Washington 99352 [R. G. S.]; and Radiation Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892-7362 [C. E. L.]
Few studies have prospectively examined endogenous hormone levels as risk factors for breast cancer. The present study compares prediagnostic hormone levels using stored serum from breast cancer cases and controls selected from the Life Span Study population of the Radiation Effects Research Foundation in Hiroshima and Nagasaki, Japan. Stored serum samples collected in 1968–1970 were assayed for 72 women subsequently diagnosed with breast cancer and 150 control subjects in 72 case-control sets matched on age, date of blood collection, exposure, radiation dose, and city. Serum levels were determined for sex hormone binding globulin, total estradiol (E2), bioavailable E2, dehydroepiandrosterone sulfate, and prolactin. Matched case-control comparisons of hormone levels were carried out by conditional logistic regression and were adjusted for menopausal status at the time of blood drawing. The odds ratio per unit log change in bioavailable E2 was 2.2 [95% confidence interval (CI), 1.02–5.3] for all subjects, and 2.3 (95% CI, 0.55–6.8) and 2.1 (95% CI, 0.55–9.7), respectively, based only on premenopausal or postmenopausal serum. The estimated odds ratios in each quintile of bioavailable E2 level, using the lowest quintile as referent, were 1.00, 1.89, 1.43, 3.45, and 3.37 (P for trend = 0.035). For sex hormone binding globulin, the overall odds ratio was 0.58 (95% CI, 0.14–2.26), and 1.00 (95% CI, 0.19–5.45) and 0.21 (95% CI, 0.02–1.88) based on premenopausal and postmenopausal serum, respectively. This study offers further prospective support for the hypothesis that a high level of biologically available E2 is a risk factor for the subsequent development of breast cancer.
This article has been cited by other articles:
|
|
 |
|
  F. Xue and K. B Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, A. H. Eliassen, P. Sluss, and S. E. Hankinson A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast Cancer J. Clin. Oncol., April 20, 2007; 25(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, A. H. Eliassen, S. A. Missmer, H. Baer, J. Rich-Edwards, K. B. Michels, R. L. Barbieri, M. Dowsett, and S. E. Hankinson Birthweight and Body Size throughout Life in Relation to Sex Hormones and Prolactin Concentrations in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2494 - 2501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Michels, K. L. Terry, and W. C. Willett Longitudinal Study on the Role of Body Size in Premenopausal Breast Cancer Arch Intern Med, November 27, 2006; 166(21): 2395 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Eliassen, S. A. Missmer, S. S. Tworoger, D. Spiegelman, R. L. Barbieri, M. Dowsett, and S. E. Hankinson Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst, October 4, 2006; 98(19): 1406 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Russo, S. V. Fernandez, P. A. Russo, R. Fernbaugh, F. S. Sheriff, H. M. Lareef, J. Garber, and I. H. Russo 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells FASEB J, August 1, 2006; 20(10): 1622 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Eliassen, S. A. Missmer, S. S. Tworoger, and S. E. Hankinson Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer: Does the Association Vary by a Woman's Predicted Breast Cancer Risk? J. Clin. Oncol., April 20, 2006; 24(12): 1823 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, P. Sluss, and S. E. Hankinson Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women Cancer Res., February 15, 2006; 66(4): 2476 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Kaaks, S Rinaldi, T J Key, F Berrino, P H M Peeters, C Biessy, L Dossus, A Lukanova, S Bingham, K-T Khaw, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition Endocr. Relat. Cancer, December 1, 2005; 12(4): 1071 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A Khan, D Bhandare, and R T Chatterton Jr The local hormonal environment and related biomarkers in the normal breast Endocr. Relat. Cancer, September 1, 2005; 12(3): 497 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kaaks, F. Berrino, T. Key, S. Rinaldi, L. Dossus, C. Biessy, G. Secreto, P. Amiano, S. Bingham, H. Boeing, et al. Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC) J Natl Cancer Inst, May 18, 2005; 97(10): 755 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lonning Exemestane for Breast Cancer Prevention: A Feasible Strategy? Clin. Cancer Res., January 15, 2005; 11(2): 918s - 924s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Missmer, A. H. Eliassen, R. L. Barbieri, and S. E. Hankinson Endogenous Estrogen, Androgen, and Progesterone Concentrations and Breast Cancer Risk Among Postmenopausal Women J Natl Cancer Inst, December 15, 2004; 96(24): 1856 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McDonald, M. G. Mandel, P. A. Marchbanks, S. G. Folger, J. R. Daling, G. Ursin, M. S. Simon, L. Bernstein, B. L. Strom, S. A. Norman, et al. Alcohol Exposure and Breast Cancer: Results of the Women's Contraceptive and Reproductive Experiences Study Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2106 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Maskarinec, A. A. Franke, A. E. Williams, S. Hebshi, C. Oshiro, S. Murphy, and F. Z. Stanczyk Effects of a 2-Year Randomized Soy Intervention on Sex Hormone Levels in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1736 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, A. H. Eliassen, B. Rosner, P. Sluss, and S. E. Hankinson Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer Cancer Res., September 15, 2004; 64(18): 6814 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Cologne, G. B Sharp, K. Neriishi, P. K Verkasalo, C. E Land, and K. Nakachi Improving the efficiency of nested case-control studies of interaction by selecting controls using counter matching on exposure Int. J. Epidemiol., June 1, 2004; 33(3): 485 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endogenous Hormones and Breast Cancer Collaborativ Free Estradiol and Breast Cancer Risk in Postmenopausal Women: Comparison of Measured and Calculated Values Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1457 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bernichtein, C. Kayser, K. Dillner, S. Moulin, J. J. Kopchick, J. A. Martial, G. Norstedt, O. Isaksson, P. A. Kelly, and V. Goffin Development of Pure Prolactin Receptor Antagonists J. Biol. Chem., September 19, 2003; 278(38): 35988 - 35999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ahsan and A. G. Rundle Measures of genotype versus gene products: promise and pitfalls in cancer prevention Carcinogenesis, September 1, 2003; 24(9): 1429 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Endogenous Hormones Breast Cancer Collaborative Gr Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women J Natl Cancer Inst, August 20, 2003; 95(16): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Endogenous Hormones and Breast Cancer Collabor Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies J Natl Cancer Inst, April 17, 2002; 94(8): 606 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Stevens and L. Hilakivi-Clarke Alcohol exposure in utero and breast cancer risk later in life Alcohol Alcohol., May 1, 2001; 36(3): 276 - 277. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
